Real-World Studies
Baseline PRO burden linked to worse survival and toxicity in CLL/SLL trial analysis
Abuhelwa et alTherapeutic advances in hematology
A pooled retrospective analysis of individual patient data from three randomized clinical trials (RESONATE, RESONATE-2, and HELIOS) evaluated the frequency and prognostic value of baseline European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 patient-reported outcome (PRO) thresholds in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) initiating ibrutinib-based therapy.
Among 1,238 evaluated patients, baseline PRO burden was substantial, with 74% (n = 920) reporting at least one clinically important domain and 32% (n = 395) reporting five or more clinically important domains. Multivariable Cox proportional hazards analysis demonstrated that each incremental clinically important domain was independently predictive of worse overall survival (adjusted HR 1.07, 95% CI 1.04–1.11; p < 0.001), inferior progression-free survival (adjusted HR 1.03, 95% CI 1.00–1.06; p = 0.047), and an increased risk of grade 3 or higher adverse events (adjusted HR 1.03, 95% CI 1.01–1.06; p = 0.006).
Comparing extreme patient cohorts revealed that individuals reporting five or more clinically important domains at baseline faced a more than two-fold increased risk of mortality (adjusted HR 2.04, 95% CI 1.42–2.94; p < 0.001) and a significantly higher likelihood of experiencing grade 3 or higher toxicity (adjusted HR 1.47, 95% CI 1.17–1.85; p < 0.001) relative to patients without any clinically important PRO domains. Analysis of individual domains showed that physical function offered the highest prognostic accuracy for overall survival (C-index = 0.63). These data underscore the utility of baseline EORTC QLQ-C30 thresholds to guide clinical risk stratification and identify candidates for tailored supportive interventions.
Key Takeaways
- In a pooled analysis of 1,238 patients with CLL/SLL initiating ibrutinib-based therapy, each additional clinically important baseline EORTC QLQ-C30 domain was independently associated with worse overall survival (adjusted HR 1.07, 95% CI 1.04–1.11; p < 0.001) and progression-free survival (adjusted HR 1.03, 95% CI 1.00–1.06; p = 0.047).
- Patients reporting five or more clinically important baseline PRO domains experienced significantly worse overall survival (adjusted HR 2.04, 95% CI 1.42–2.94; p < 0.001) and an increased risk of grade 3 or higher adverse events (adjusted HR 1.47, 95% CI 1.17–1.85; p < 0.001) compared to patients with no clinically important domains.
- Physical function was identified as the single strongest individual baseline prognostic domain for predicting overall survival (C-index = 0.63).
Read the original sourceTherapeutic advances in hematology
